ArticleMetabolic brain disease2026
Neuroprotective potential of phloroglucinol in focal cerebral ischemia in rats: a mechanistic study.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salvianolic Acid B Attenuates Excitotoxic Neuronal Injury After Transient Cerebral Ischemia.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke remains a leading cause of mortality and disability worldwide, with limited therapeutic options that effectively target its complex pathophysiology. This study evaluates the neuroprotective potential of phloroglucinol (PH), a polyphenolic compound with known antioxidant and anti-inflammatory properties, in a rat model of focal cerebral ischemia induced by middle cerebral artery occlusion (MCAO). Animals were randomly assigned to different groups. Phloroglucinol was administered intraperitoneally at doses of 15 and 30 mg/kg, beginning immediately after a 1-hour MCAO injury and continuing once daily for 21 days. Treatment with phloroglucinol significantly improved neurological deficit, muscle strength, locomotor activity, and cognitive performance (Morris Water Maze (MWM) and Novel Object Recognition Test (NORT) conducted at the last week of study) compared to untreated MCAO rats. Biochemical analyses revealed that phloroglucinol reduced oxidative stress markers (malondialdehyde (MDA), nitrite), restored antioxidant defenses (glutathione (GSH) and catalase, and attenuated neuroinflammation by lowering interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels. Additionally, phloroglucinol decreased cerebral infarct volume and preserved blood-brain barrier (BBB) integrity. However, it also improved the mitochondrial functions by increasing the gene expression of hypoxia-inducing factor 1 alpha (HIF-1α) and Transcription factor A, mitochondrial (TFAM), reducing caspase-3 activation and inducing nitric oxide synthase (iNOS) gene expression, and enhancing nuclear factor erythroid 2-related factor 2/ Heme oxygenase-1 (Nrf-2/HO-1) expression. Molecular docking studies suggested that phloroglucinol may exert its effects via interaction with the Kelch-like ECH-associated protein 1 (KEAP1)-Nrf-2 pathway. These findings highlight phloroglucinol as a promising multi-target neuro-protective agent for ischemic stroke, warranting further investigation for clinical translation.
Indexed as
Identifiers
41533183What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.